The bibliographic citations are derived from Medline databases through the National Library of Medicine.
Respiratory care
Inflammation
Oral toxicity
Chemotherapy
Meister R, Wittig T, Beuscher N, de Mey C (1999). Efficacy and tolerability
of myrtol standardized in long-term treatment
of chronic bronchitis. A double-blind, placebo-controlled study. Arzneimittelforschung,
49(4):351-8.
Summary:
Myrtol was found to minimize acute exacerbations of chronic bronchitis in human
subjects. It was as well tolerated as the
placebo. Myrtol standardized reduced the need for antibiotics, reduced the intensity
and frequency of acute episodes, and
minimized the debility of chronic coughing and expectoration.
Sengespeik HC, Zimmermann T, Peiske C, de Mey C (1998). Myrtol standardized
in the treatment of acute and chronic
respiratory infections in children. A multicenter post-marketing surveillance
study. Arzneimittelforschung, 48(10):990-4.
Summary: Myrtol standardized was used with 511 children with acute and
chronic sinusitis, bronchitis and sinubronchitis. Symptoms
of headache, trigeminal pain, mucus in the pharynx, and paranasal sensitivity
disappeared after treatment for two weeks in
more than 90% of the children. Difficulty clearing sputum and clogged
nasal passages were no longer observed in more
than 60% of the children. Adverse drug reactions were less than 1%.
The majority of physicians, patients, and parents
judged the efficacy to be very good or good.
Federspil P, Wulkow R, Zimmermann T (1997). Effects of standardized Myrtol in
therapy of acute sinusitis--results of a
double-blind, randomized multicenter study compared with placebo. Laryngorhinootologie,
76(1):23-7.
Summary: The efficacy and safety of Myrtol standardized was studied in 331 human
patients with acute sinusitis. It was found to be
significantly more effective than the placebo. The results supported the
use of essential oils like myrtol as a treatment for
acute sinusitis. The researchers concluded that use of myrtol instead
of antibiotics as a first choice of treatment is confirmed
by the literature.
Grassmann
J, Hippeli S, Dornisch K, Rohnert U, Beuscher N, Elstner EF. (2000). Antioxidant properties of essential oils.
Possible explanations for their anti-inflammatory effects. Arzneimittelforschung,
50(2):135-9.
Summary:
These researchers summarize the effects of essential oils on the the inflammatory
process. They state that Myrtol
Standardized and Eucalyptus oil reduce inflammation by interacting with oxygen
radicals, buffering biochemical damage
triggered by infections.
Uehleke
H, Brinkschulte-Freitas M (1979). Oral toxicity of an essential oil from
myrtle and adaptive liver stimulation. Toxicology,
12(3):335-42.
Summary:
Oral toxicity of myrtle essential oil was studied in mice. The study concluded
that continuous use in humans of 1 - 2 ml per day
is too low to cause liver damage.
Moghimi
HR, Williams AC, Barry BW (1998). Enhancement by terpenes of 5-fluorouracil
permeation through the stratum corneum:
model solvent approach. J Pharm Pharmacol, 50(9):955-64.
Summary:
Using human epidermis, 26 different terpenes were tested to enhance the permeability
of 5-flourouracil, a chemotherapy agent,
through skin. Data obtained showed that cineole enhances the effect of 5-fourouracil
much more than limonene. Cineole is the
primary compound in essential oils from the Myrtaceae and Lauraceae families,
such as myrtle, eucalyptus, tea tree, and cinnamon.
Last updated 04.14.05
Use the back button on your browser to return to your previous page